---
title: "Shandong Xinhua Pharmaceutical Receives Drug Registration Certificate for Glucosamine Sulfate Capsules"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275286848.md"
description: "Shandong Xinhua Pharmaceutical Company Limited has received a Drug Registration Certificate for its Glucosamine Sulfate Capsules for Suspension. This approval, granted after a regulatory review, classifies the product as a Category A non-prescription drug. The company must adhere to pharmaceutical production quality management standards before starting production and sales. No other beneficiary organizations were mentioned in the announcement."
datetime: "2026-02-09T08:33:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275286848.md)
  - [en](https://longbridge.com/en/news/275286848.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275286848.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275286848.md) | [繁體中文](https://longbridge.com/zh-HK/news/275286848.md)


# Shandong Xinhua Pharmaceutical Receives Drug Registration Certificate for Glucosamine Sulfate Capsules

Shandong Xinhua Pharmaceutical Company Limited announced that it has received the Drug Registration Certificate for its Glucosamine Sulfate Capsules for Suspension. The approval was granted after regulatory review in accordance with the Pharmaceutical Administration Law of the People’s Republic of China and relevant regulations. The product is approved as a Category A non-prescription drug, and the company is required to comply with pharmaceutical production quality management standards before commencing production and sales. No other beneficiary organizations were mentioned in the announcement. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Xinhua Pharmaceutical Company Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260209-12019080), on February 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [Xinhua Pharm (000756.CN)](https://longbridge.com/en/quote/000756.CN.md)
- [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/en/quote/588130.CN.md)
- [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/en/quote/159992.CN.md)
- [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/en/quote/516930.CN.md)
- [China Universal 800 Health Care ETF (159929.CN)](https://longbridge.com/en/quote/159929.CN.md)
- [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/en/quote/512290.CN.md)
- [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/en/quote/513120.CN.md)
- [Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII) (520500.CN)](https://longbridge.com/en/quote/520500.CN.md)
- [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/en/quote/510660.CN.md)
- [China Universal CNI HK Connect Innovative Drugs Industry ETF (159570.CN)](https://longbridge.com/en/quote/159570.CN.md)
- [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/en/quote/159506.CN.md)
- [Hwabao WP CSI Pharmaceuticals ETF (562050.CN)](https://longbridge.com/en/quote/562050.CN.md)
- [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/en/quote/512010.CN.md)
- [Guotai SSE STAR Brand Name Drug ETF (589720.CN)](https://longbridge.com/en/quote/589720.CN.md)
- [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/en/quote/520690.CN.md)
- [SHANDONG XINHUA (00719.HK)](https://longbridge.com/en/quote/00719.HK.md)
- [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/en/quote/520880.CN.md)
- [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/en/quote/159316.CN.md)

## Related News & Research

- [Henlius Biotech Doses First Patient in Phase 2/3 Breast Cancer Drug Study; Shares Slip 3%](https://longbridge.com/en/news/277421361.md)
- [08:03 ETDecentralized Clinical Trial Validates Novel "Fasting Mimetic" Formulation for Cardiometabolic Health](https://longbridge.com/en/news/277468910.md)
- [Fangzhou, Youcare Partner To Advance AI In Chronic Disease Care](https://longbridge.com/en/news/277337723.md)
- [Sanofi bets on Sino Biopharm’s transplant drug in $1.5bn licensing deal](https://longbridge.com/en/news/277818646.md)
- [Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 billion](https://longbridge.com/en/news/277695972.md)